Botulinum toxin treatment in upper limb spasticity: treatment consistency

Eur J Paediatr Neurol. 2012 May;16(3):237-42. doi: 10.1016/j.ejpn.2011.07.013. Epub 2011 Sep 8.

Abstract

This study assessed treatment consistency of botulinum toxin administration in spastic upper limbs under pragmatic conditions, as derived through stability of dosages and between injections intervals. Over a period of 8 years, 153 children (81 with bilateral spastic cerebral palsy, 72 with unilateral) were treated according to accepted, experience-based guidelines with Botox and Dysport. Treatment response was based on assessment of spasticity and attainment of pre-determined goals at 3, 6 and 12 months post each treatment. Mean age at treatment onset was 6y 4mo (SD: 4y 10mo), median F/U, 2.5 years (4 months-6 8/12 years). Number of injection sessions was 1-10; few had more than 6 sessions. In 106 (69.28%) children, more than one anatomic regions of the limb were injected. Most (56.2%), had at least two injection sessions; median time interval between the sessions was 9 months (IQR: 4-35 months, similar for unilateral and bilateral cerebral palsy, p = 0.874). Children >4 years old at the first treatment had longer intervals between sessions (25.8%) compared to younger ones (p = 0.010). The mixed effects models demonstrated that botulinum toxin dosage was stable over subsequent visits (p = 0.144) and that intermediate intervals for subsequent visits were similar to the first one (p = 0.279).

MeSH terms

  • Adolescent
  • Botulinum Toxins, Type A / administration & dosage*
  • Cerebral Palsy / drug therapy*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Male
  • Muscle Spasticity / drug therapy
  • Neuromuscular Agents / administration & dosage*
  • Upper Extremity

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A
  • abobotulinumtoxinA